Opana ER Removal a Tale of Two Stories

On June 8, FDA “requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.”  Here’s <a href=”https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm” target=”_blank” rel=”noopener”>the full story</a> from FDA.

Here’s <a href=”https://blogs.fda.gov/fdavoice/index.php/2017/05/fda-commissioner-asks-staff-for-more-forceful-steps-to-stem-the-opioid-crisis/” target=”_blank” rel=”noopener”>another important story</a> from May 23 that many overlooked, <strong>FDA Commissioner Asks Staff for ‘More Forceful Steps’ to Stem the Opioid Crisis</strong>: “As Commissioner, my highest initial priority is to take immediate steps to reduce the scope of the epidemic of opioid addiction. I believe the Food and Drug Administration continues to have an important role to play in addressing this crisis, particularly when it comes to reducing the number of new cases of addiction…Today, I sent an email to all of my colleagues at FDA, sharing with them the first steps I plan to take to better achieve this public health goal. With this, my first post to the FDA Voice blog, I also wanted to share my plans with you.”  <a href=”/contact-pdg/”>Click here to contact us</a> about your development of a solution to the problem of addiction.

print